| 1057c583-4241-42dd-a502-30eb96a680bf | Efeitos adversos de ganglioplégicos, não classificados em outra parte | Y512 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11574 | 1 | 2021-05-25T19:40:03.670000+00:00 | 2021-05-25T19:40:03.670000+00:00 |
| bc58c4ee-a1d7-4189-a04d-9c4fe4486092 | Efeitos adversos de agonistas predominantemente alfa-adrenorreceptores, não classif. em outra parte | Y514 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11576 | 1 | 2021-05-25T19:40:03.670000+00:00 | 2021-05-25T19:40:03.670000+00:00 |
| f5d561ae-c853-445c-a958-a905a17fd152 | Efeitos adversos de agonistas predominantemente beta-adrenorreceptores, não classif. em outra parte | Y515 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11577 | 1 | 2021-05-25T19:40:03.670000+00:00 | 2021-05-25T19:40:03.670000+00:00 |
| 0628e1c4-eace-4a97-8074-9a4b4d81b4ca | Efeitos adversos de antagonistas alfa-adrenorreceptores, não classificados em outra parte | Y516 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11578 | 1 | 2021-05-25T19:40:03.671000+00:00 | 2021-05-25T19:40:03.671000+00:00 |
| 64a2faf5-151d-4825-b5f0-74628dde0d01 | Doador de córnea | Z525 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 12117 | 1 | 2021-05-25T19:40:03.685000+00:00 | 2021-05-25T19:40:03.685000+00:00 |
| e867d4a1-9540-460f-9d59-50ae60354b7b | Efeitos adversos do ácido valpróico | Y465 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11539 | 1 | 2021-05-25T19:40:03.670000+00:00 | 2021-05-25T19:40:03.670000+00:00 |
| 8df1d318-3acd-4c4b-840e-8fc140a45574 | Efeitos adversos de drogas antiparkinsonianas | Y467 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11541 | 1 | 2021-05-25T19:40:03.670000+00:00 | 2021-05-25T19:40:03.670000+00:00 |
| e910205e-9536-40fe-a53a-3aa0dcf82275 | Efeitos adversos de benzodiazepínicos | Y471 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11544 | 1 | 2021-05-25T19:40:03.670000+00:00 | 2021-05-25T19:40:03.670000+00:00 |
| 9dc8361d-0e8e-4363-8bee-706bc610f03d | Efeitos adversos de glicosídeos estimulantes do coração e substâncias de ação semelhante | Y520 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11582 | 1 | 2021-05-25T19:40:03.671000+00:00 | 2021-05-25T19:40:03.671000+00:00 |
| 21dd8a02-bff5-48cd-a66a-2e7b74de582a | Efeitos adversos de antagonistas do cálcio [inibidores do cálcio] | Y521 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11583 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| ceafc5c8-16c5-4c18-b3a7-b9fca6411a8a | Efeitos adversos de outras drogas antidisrrítmicas, não classificadas em outra parte | Y522 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11584 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| e27e0441-081a-4345-9b85-67ef3df95d12 | Efeitos adversos de vasodilatadores coronarianos, não classificados em outra parte | Y523 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11585 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| dec5b3df-0c6d-497c-a453-57eab7bed9be | Efeitos adversos de inibidores da enzima de conversão da angiotensina | Y524 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11586 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| d7436c33-742f-4ec5-b524-333e6fae63f7 | Efeitos adversos de outras drogas anti-hipertensivas, não classificadas em outra parte | Y525 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11587 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 26bc047b-2a06-459e-9f4a-57cd3973113f | Efeitos adversos de drogas anti-hiperlipidêmicas e antiarterioscleróticas | Y526 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11588 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 497955a3-e0da-4fe3-aabe-7ffa164c75ba | Efeitos adversos de vasodilatadores periféricos | Y527 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11589 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| a0d9e9eb-100d-4a1f-9b1f-58c376f9bba7 | Efeitos adversos de drogas antivaricosas, incluindo os agentes esclerosantes | Y528 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11590 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| ef1eca18-f354-4e92-b877-403e6140807d | Efeitos adversos de outras drogas que atuam primar. s/o apar. cardiovascular e as não especificadas | Y529 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11591 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 1b542d46-93c3-4287-9e49-88e0475cda69 | Efeitos adversos de substancias que atuam primáriamente sobre o aparelhogastrointestinal | Y53 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 14117 | 1 | 2021-05-25T19:40:03.696000+00:00 | 2021-05-25T19:40:03.696000+00:00 |
| e9a87781-e853-4411-8a7a-bef13e10d2bd | Efeitos adversos de antagonistas dos receptores h2 da histamina | Y530 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11592 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 0f2548b3-15d8-4e2a-88dc-b0162278389e | Efeitos adversos de outros medicamentos antiácidos e anti-secreção gástrica | Y531 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11593 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 55806d97-dc07-4426-b11b-1cff3c5ce013 | Efeitos adversos de laxativos estimulantes | Y532 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11594 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 2940e660-4483-4041-b69e-58a5ce3d2760 | Efeitos adversos de laxativos salinos e osmóticos | Y533 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11595 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 9f4437de-538f-4489-aa25-e5df77dcaa33 | Efeitos adversos de outros laxativos | Y534 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11596 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 5d60c321-092f-4d3b-a1e8-1183bd164596 | Efeitos adversos de medicamentos que facilitam a digestão | Y535 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11597 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| e2636b04-cb6e-4e02-80b5-25b816ba1928 | Efeitos adversos de eméticos | Y537 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11599 | 1 | 2021-05-25T19:40:03.673000+00:00 | 2021-05-25T19:40:03.673000+00:00 |
| a951ec6f-4aae-475d-8db3-1cbfbe424c23 | Efeitos adversos de substâncias que atuam primar. s/o aparelho gastrointestinal, não especificadas | Y539 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11601 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 79605ae9-df5a-4b6d-a05b-219ac145e27e | Efeit adverso subst que atuam primáriamente sobre metabolismo da água sais minerais eácido urico | Y54 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 14118 | 1 | 2021-05-25T19:40:03.696000+00:00 | 2021-05-25T19:40:03.696000+00:00 |
| 0cef7a36-7809-4f01-884b-42c371af0939 | Efeitos adversos de antagonistas dos mineralocorticóides [antagonistas da aldosterona] | Y541 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11603 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| dd8ab296-f28c-489e-b0b2-e8a21ac85376 | Efeitos adversos de inibidores da anidrase carbônica | Y542 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11604 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| c700af03-3341-44bc-8229-9c398ee43c3f | Efeitos adversos de derivados da benzotiadiazína | Y543 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11605 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| aefb63b5-359a-4868-a77a-f5ed88c7df8c | Efeitos adversos de diuréticos de alça | Y544 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11606 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 6e8312cc-c770-47d5-8c3b-b61bd1197eb6 | Efeitos adversos de outros diuréticos | Y545 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11607 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 6ba8169b-d3d5-49e5-9cd8-52db131d6549 | Efeitos adversos de agentes que atuam sobre o equilíbrio eletrolítico, calórico e hídrico | Y546 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11608 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 6127a452-906b-4a98-b9eb-7ebca315374c | Efeitos adversos de medicamentos que atuam sobre o metabolismo de cálcio | Y547 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11609 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 566fd674-7bed-415c-8f58-46386718cdf4 | Efeitos adversos de drogas que atuam sobre o metabolismo de ácido úrico | Y548 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11610 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 2382e1f5-0270-4a8f-b162-fed5ab5d4d60 | Efeitos adversos de sais minerais não classificados em outra parte | Y549 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11611 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 47488f7f-992b-4c5c-a87c-111820f8b63d | Efeito adverso subst que atuam primáriamente músculos lisos e esqueléticos o aparelho respiratório | Y55 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 14119 | 1 | 2021-05-25T19:40:03.696000+00:00 | 2021-05-25T19:40:03.696000+00:00 |
| 0441e4ee-93a8-418b-a352-c0a2d7e2910d | Efeitos adversos de ocitócicos | Y550 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11612 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 9695c471-3bbb-4942-bb96-fd11e6e55074 | Efeitos adversos de relaxantes da muscul. esquelética [bloqueadores neuromusculares] [curarizantes] | Y551 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11613 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 265a68c7-90cc-4d98-8b72-aba99dda0b40 | Efeitos adversos de outras substâncias que atuam primar. sobre os músculos e as não especificadas | Y552 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11614 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 15d126c5-0d75-4741-a45d-599d13acdc50 | Efeitos adversos de antitússicos | Y553 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11615 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 44496f08-2387-4499-a177-e684152aa400 | Efeitos adversos de expectorantes | Y554 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11616 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 69537931-e8f1-4f02-aca0-e8d1a4dbb25e | Efeitos adversos de drogas anti-resfriado comum | Y555 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11617 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| de9bbd4d-2083-472a-9850-1fd70dbc2caa | Efeitos adversos de antiasmáticos, não classificados em outra parte | Y556 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11618 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| e0e9624a-32aa-46da-ab15-e92b7ef9aa10 | Efeitos adversos de outras drogas que atuam sobre o aparelho respiratório e as não especificadas | Y559 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11619 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 67e52930-c2e6-4a1b-a9c1-d48321572a14 | Efeitos adversos de bloqueadores nervosos de ação central e adrenérgicos, não classif. noutra parte | Y518 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11580 | 1 | 2021-05-25T19:40:03.671000+00:00 | 2021-05-25T19:40:03.671000+00:00 |
| 8fbb1515-8ea1-43b0-b8d6-831f854792c1 | Efeitos adversos de outras drogas que atuam primar. s/ o sist. nerv. autônomo e as não especificadas | Y519 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11581 | 1 | 2021-05-25T19:40:03.671000+00:00 | 2021-05-25T19:40:03.671000+00:00 |
| 35a28d63-d994-41e4-a810-7008d58cfb80 | Efeitos adversos de antidiarréicos | Y536 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11598 | 1 | 2021-05-25T19:40:03.672000+00:00 | 2021-05-25T19:40:03.672000+00:00 |
| 6b6baa61-b041-44e3-aa7d-7cd03e2867cd | Efeitos adversos de ceratolíticos, ceratoplásticos e outros medicamentos e preparações capilares | Y564 | 708dcbc4-baf1-4882-8fb6-24914a6c152e | f8641bf6-74cd-4bb9-be22-22cbb555885c | 11624 | 1 | 2021-05-25T19:40:03.674000+00:00 | 2021-05-25T19:40:03.674000+00:00 |